Received: 14 May 2022
Accepted: 9 July 2022
First Online: 22 July 2022
Change Date: 12 October 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s40560-022-00638-z
: The study protocol was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine (R2653).
: Not applicable.
: Koji Kawakami has received research funds from Eisai Co., Ltd.; Kyowa Kirin Co., Ltd.; Sumitomo Dainippon Pharma Co., Ltd.; Pfizer Inc.; Stella Pharma Corporation; CMIC Co., Ltd.; Suntory Beverage & Food Ltd.; Mitsubishi Corporation, and Real World Data Co., Ltd.; consulting fees from LEBER Inc.; JMDC Inc.; Shin Nippon Biomedical Laboratories Ltd.; Kaken Pharmaceutical Co., Ltd.; and Advanced Medical Care Inc.; executive compensation from Cancer Intelligence Care Systems; Inc.; honorarium from Mitsubishi Chemical Holdings Corporation, Mitsubishi Corporation, and Pharma Business Academy; and holds stock in Real World Data Co., Ltd.